Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – June 2019
Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms—some of which are highly prevalent—including cognitive impairment, mood disorders, psychosis, sleep disruption, and autonomic dysfunction. Experts report that some nonmotor symptoms can be more disabling for PD patients than the characteristic motor symptoms and, for many of these symptoms, few good treatment options exist. Opportunity for premium pricing and limited competition has spurred pharma’s interest in PD nonmotor symptoms and a number of agents are in early-phase development. Understanding neurologists’ prioritization of these symptoms, current management strategies, and prescribers’ receptivity for new entrants is crucial for developers advancing new drugs for this understudied and underdeveloped market space.
Geographies: United States
Primary research: Survey of 100 neurologists
Key drugs covered: Northera, Nuplazid, rivastigmine, and others
Key nonmotor symptoms covered: Dementia, orthostatic hypotension, psychosis, sleep disruption, and others
Key insights provided:
DRG’s Special Topics reports use quantitative primary research to assess evolving trends and market opportunities in dynamic disease areas. Insights from this report on Parkinson’s disease will help developers identify promising areas of development or licensing and gauge the competitiveness and sales potential of their assets in the PD market.
Already a Client? Log in to access this report.
Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.